基于FFRCT的功能性CAD-RADS对冠状动脉疾病患者治疗管理和预后的影响
研究提出整合CCTA衍生血流储备分数(FFRCT)的功能性CAD-RADS分类系统,在回顾性多中心队列(n=466)中以实际临床治疗为参考标准评估其指导治疗策略的表现,并在前瞻性两臂队列(FFRCT组566例 vs CCTA组567例)中评估其1年预后价值。功能性CAD-RADS指导治疗决策的AUC为0.828,优于解剖性CAD-RADS的0.681(p<0.001),与FFR的0.848相当(p=0.253);使30.0%患者(n=140)的治疗方案发生修订(NRI=0.369,p<0.001)。功能性CAD-RADS是1年不良结局的独立预测因子,一致性指数为0.795,解剖性CAD-RADS为0.751。
要点
- 功能性CAD-RADS指导治疗决策的AUC为0.828,优于解剖性CAD-RADS的0.681(p<0.001)。
- 功能性CAD-RADS使30.0%患者(n=140)的治疗方案发生修订(NRI=0.369,p<0.001)。
- 功能性CAD-RADS是1年不良结局的独立预测因子,一致性指数0.795,解剖性CAD-RADS为0.751。
核心结论
- 新型功能性CAD-RADS在指导治疗决策方面较解剖性CAD-RADS具有增量价值,在真实世界场景中1年预后能力与解剖性CAD-RADS相当。
研究设计与样本
- 首先在回顾性多中心队列(n=466,所有患者均行CCTA和有创FFR)中提出功能性CAD-RADS并以实际临床治疗为参考标准评估其指导治疗策略的表现;其次在前瞻性两臂队列(FFRCT组566例 vs CCTA组567例)中,随访1年后比较FFRCT组(n=513)的功能性CAD-RADS与CCTA组(n=511)的解剖性CAD-RADS,采用Cox比例风险模型确定不良结局风险患者。
诊断标准与关键数值
- 功能性CAD-RADS指导治疗决策的AUC为0.828,解剖性CAD-RADS为0.681(p<0.001)。
- 功能性CAD-RADS指导治疗决策的AUC为0.828,FFR为0.848(p=0.253)。
- 功能性CAD-RADS使30.0%患者(n=140)的治疗方案发生修订,NRI=0.369(p<0.001)。
- 功能性CAD-RADS预测1年结局的一致性指数为0.795,解剖性CAD-RADS为0.751。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To propose a novel functional Coronary Artery Disease-Reporting and Data System (CAD-RADS) category system integrated with coronary CT angiography (CCTA)-derived fractional flow reserve (FFRCT) and to validate its effect on therapeutic decision and prognosis in patients with coronary artery disease (CAD).
METHODS: Firstly, we proposed a novel functional CAD-RADS and evaluated the performance of functional CAD-RADS for guiding treatment strategies with actual clinical treatment as a reference standard in a retrospective multicenter cohort with CCTA and invasive FFR performed in all patients (n = 466). Net reclassification improvement (NRI) of functional CAD-RADS over anatomical CAD-RADS was calculated. Secondly, the prognostic value of functional CAD-RADS in a prospective two-arm cohort (566 [FFRCT arm] vs. 567 [CCTA arm]) was calculated, after a 1-year follow-up, functional CAD-RADS in FFRCT arm (n = 513) and anatomical CAD-RADS in CCTA arm (n = 511) to determine patients at risk of adverse outcomes were compared with a Cox hazard proportional model.
RESULTS: Functional CAD-RADS demonstrated superior value over anatomical CAD-RADS (AUC: 0.828 vs. 0.681, p < 0.001) and comparable performance to FFR (AUC: 0.828 vs. 0.848, p = 0.253) in guiding therapeutic decisions. Functional CAD-RADS resulted in the revision of management plan as determined by anatomical CAD-RADS in 30.0% of patients (n = 140) (NRI = 0.369, p < 0.001). Functional CAD-RADS was an independent predictor for 1-year outcomes with indexes of concordance of 0.795 and the corresponding value was 0.751 in anatomical CAD-RADS.
CONCLUSION: The novel functional CAD-RADS gained incremental value in guiding therapeutic decision-making compared with anatomical CAD-RADS and comparable power in 1-year prognosis with anatomical CAD-RADS in a real-world scenario.
KEY POINTS: • The novel functional CAD-RADS category system with FFRCT integrated into the anatomical CAD-RADS categories was originally proposed. • The novel functional CAD-RADS category system was validated superior value over anatomical CAD-RADS (AUC: 0.828 vs. 0.681, p < 0.001) in guiding therapeutic decisions and revised management plan in 30.0% of patients as determined by anatomical CAD-RADS (net reclassification improvement index = 0.369, p < 0.001). • Functional CAD-RADS was an independent predictor with an index of concordance of 0.795 and 0.751 in anatomical CAD-RADS for 1-year prognosis of adverse outcomes.
引用
- Tang, Qiao, Zhang, et al. Functional CAD-RADS using FFRCT on therapeutic management and prognosis in patients with coronary artery disease. Eur Radiol. 2022. PMID: 35258672. doi:10.1007/s00330-022-08618-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。